Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
As a leading pharmaceutical company with a focus on neuroscience, cardiometabolic, cancer, and immunology, Eli Lilly has ...
Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates. The disappointment led to a [15% plunge in Lilly’s shares]( ...